Clinical Trials

57 enrolled

Prostatic Neoplasms

NCT04577833 2026-03-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04662580 2026-03-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT05818683 2026-02-13

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Phase 1 Recruiting

277 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

18 enrolled

Metastatic Hormone Refractory Prostate Cancer

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

48 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Phase 1 Recruiting

250 enrolled

Prostatic Neoplasms

NCT02913196 2025-05-23

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

16 enrolled

Prostate Cancer Metastatic

NCT01792687 2025-03-04

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

6 enrolled

Prostatic Neoplasms

NCT04421222 2025-02-28

EPI-7386

Phase 1 Terminated

71 enrolled

Prostatic Neoplasms

NCT05295927 2025-02-03

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1 Terminated

3 enrolled

Prostatic Neoplasms

NCT04291664 2024-10-17

PK and Dose Escalation and Expansion Study of DST-2970

Phase 1 Terminated

26 enrolled

Prostatic Neoplasms

NCT06193993 2024-01-08

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

10 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT04628988 2023-09-13

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

6 enrolled

Prostatic Neoplasms

NCT04179396 2023-06-29

RAMP

8 enrolled 8 charts

Metastatic Castration Resistant Prostate Cancer

NCT04296578 2021-08-12

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

Phase 1 Withdrawn

Prostatic Neoplasms

NCT01574937 2021-08-06

XL-184+Abiraterone in Post-Chemo CRPC

27 enrolled

Prostatic Neoplasms

NCT04889651 2021-07-22

A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers

40 enrolled

Prostatic Neoplasms

NCT02730975 2021-01-11

ABIFOOD01

42 enrolled

Prostatic Neoplasms

NCT02883166 2020-12-07

SNACK

14 enrolled

Prostatic Neoplasms

NCT02924766 2020-07-20

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

34 enrolled

Prostatic Neoplasms

NCT02001571 2013-12-05

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

24 enrolled

Prostatic Neoplasms

NCT01664728 2013-04-19

An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001

54 enrolled

Prostatic Neoplasms

NCT00910754 2013-04-12

A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

33 enrolled

Prostatic Neoplasms

NCT01017939 2013-04-12

A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer

34 enrolled